Document:

Amended and Restated Director Compensation Policy

 Exhibit 10.1  
  
 INSPIRE PHARMACEUTICALS, INC. 
  

AMENDED AND RESTATED 
 DIRECTOR
COMPENSATION POLICY 
  
 ADOPTED: March 30, 2004

  
 A. Directors. All non-employee members of the Inspire
Pharmaceuticals, Inc. (the “Company”) board of directors (the “Board”) shall receive the following compensation pursuant to the Amended and Restated Director Compensation Policy (this “Policy”): 
  

	 	1)	Cash compensation of $25,000 annually to cover general availability and participation in meetings and conference calls of the Board; 

  

	 	2)	A stock option grant in the amount of 20,000 shares will be granted to each director upon election at an annual meeting of stockholders to a three-year term, which will vest as
follows: 10,000 shares in year one (1/12th per month), 5,000 shares in year two (1/12th per month) and 5,000 shares in year three (1/12th per month); provided, however, that all vesting will cease if the director resigns from the Board or otherwise ceases to serve as director,
unless the Board determines that the circumstances warrant continuation of vesting; and 

  

	 	3)	A stock option grant in the amount of 10,000 shares will be granted to each director serving as such at the time of each annual meeting of stockholders who was not elected at such
annual meeting, which grant will be made at the time of such annual meeting (to vest 1/12th per month);
provided, however, that all vesting will cease if the director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.

  
 B. Audit Committee. In addition to the
compensation provided under any other provision of this Policy, all non-employee directors who serve on the Audit Committee will receive the following compensation: 
  

	 	1)	Cash compensation of $10,000 annually to cover general availability and participation in Audit Committee conference calls and meetings; and 

  

	 	2)	Stock option grants in the amount of 4,000 shares will be granted to each director appointed at each annual meeting of the Board of Directors to serve on the Audit Committee (to
vest 1/12th per month); provided, however, that all vesting will cease if the director resigns from
the Audit Committee or otherwise ceases to serve as an Audit Committee member (including without limitation as a result of a committee member’s term expiring without re-election), unless the Board determines that the circumstances warrant
continuation of vesting. 

			
	 Inspire Pharmaceuticals, Inc.
	  	 Page 
 2
 of 4
	 Amended and Restated Director Compensation Policy
	  	 
	 Adopted March 30, 2004
	  	 

  

 C. Compensation Committee. In addition to the compensation provided under any other provision of this
Policy, all non-employee directors who serve on the Compensation Committee will also receive the following compensation: 
  

	 	1)	Cash compensation of $5,000 annually to cover general availability and participation in Compensation Committee conference calls and meetings; and 

  

	 	2)	Stock option grants in the amount of 2,000 shares will be granted to each director appointed at each annual meeting of the Board of Directors to serve on the Compensation Committee
(to vest 1/12th per month); provided, however, that all vesting will cease if the director resigns
from the Compensation Committee or otherwise ceases to serve as a Compensation Committee member (including without limitation as a result of a committee member’s term expiring without re-election), unless the Board otherwise determines that the
circumstances warrant continuation of vesting. 

  
 D.
Corporate Governance Committee. In addition to the compensation provided under any other provision of this Policy, all non-employee directors who serve on the Corporate Governance Committee will also receive the following compensation:

  

	 	1)	Cash compensation of $5,000 annually to cover general availability and participation in Corporate Governance Committee conference calls and meetings; and 

 

	 	2)	Stock option grants in the amount of 2,000 shares will be granted to each director appointed at each annual meeting of the Board of Directors to serve on the Corporate Governance
Committee (to vest 1/12th per month); provided, however, that all vesting will cease if the director
resigns from the Corporate Governance Committee or otherwise ceases to serve as a Corporate Governance Committee member (including without limitation as a result of a committee member’s term expiring without re-election), unless the Board
otherwise determines that the circumstances warrant continuation of vesting. 

			
	 Inspire Pharmaceuticals, Inc.
	  	 Page 
 3
 of 4
	 Amended and Restated Director Compensation Policy
	  	 
	 Adopted March 30, 2004
	  	 

  

 E. Chairman of the Board. In addition to the compensation provided under any other provision of this
Policy, the director who serves as the Chairman of the Board will receive the following compensation: 
  

	 	1)	Cash compensation of $25,000 annually to cover general availability for consultations and communications with the Company’s senior management, and to work closely with the
Chief Executive Officer of the Company on key matters affecting the Company; and 

  

	 	2)	Stock option grants in the amount of 4,000 shares will be granted to the director appointed at each annual meeting of the Board of Directors to serve as Chairman of the Board (to
vest 1/12th per month); provided, however, that all vesting will cease if the director resigns from
the position of Chairman of the Board or otherwise ceases to serve as the Chairman of the Board (including without limitation as a result of the director’s term expiring without re-election), unless the Board otherwise determines that the
circumstances warrant continuation of vesting. 

  
 F.
Vice-Chairman of the Board. In addition to the compensation provided under any other provision of this Policy, the director who serves as the Vice-Chairman of the Board will also receive the following compensation: 
  

	 	1)	Cash compensation of $5,000 annually to cover general availability for consultations and communications with the Company’s senior management, and to work closely with the
Chairman of the Board and Chief Executive Officer of the Company on key matters affecting the Company; and 

  

	 	2)	Stock option grants in the amount of 2,000 shares will be granted to the director appointed at each annual meeting of the Board of Directors to serve as Vice-Chairman of the Board
(to vest 1/12th per month); provided, however, that all vesting will cease if the director resigns
from the position of Vice-Chairman of the Board or otherwise ceases to serve as the Vice-Chairman of the Board (including without limitation as a result of the director’s term expiring without re-election), unless the Board otherwise determines
that the circumstances warrant continuation of vesting. 

  
 G.
Vacancies. In the event that a director is appointed to fill a vacancy on the Board, any Committee of the Board, as Chairman of the Board or as Vice-Chairman of the Board, the Board will determine the amount of cash compensation and
stock option grants appropriate to provide such director with comparable compensation for the period such director will so serve for the remainder of the term. 
  

H. Payment/Grant Procedure. All cash compensation payments made pursuant to this Policy shall be paid quarterly in arrears as soon as practicable, but
not later than 10 days, after the last day of such quarter. 

			
	 Inspire Pharmaceuticals, Inc.
	  	 Page 
 4
 of 4
	 Amended and Restated Director Compensation Policy
	  	 
	 Adopted March 30, 2004
	  	 

  

 All stock options awarded pursuant to this Policy (other than options granted pursuant to Paragraph G) shall be
granted on the date of the annual meeting of the Board of Directors, and the exercise price for each share available under such option will be equal to the fair market value of the common stock of the Company, par value of $.001 per share (the
“Common Stock”), on the date of such grant. All stock options awarded pursuant to Paragraph G of this Policy shall be granted on the date of such appointment, and the exercise price for each share available under such option will be equal
to the fair market value of the Common Stock, on the date of such grant. 
  
 I.
Effective Date. All cash compensation provisions of this Policy shall be effective as of April 1, 2004. 
  
 All Stock option grant provisions of this Policy shall be effective for directors elected or serving as of the annual meeting of stockholders to be held in 2004, or
appointed to a Committee or as Chairman of the Board or Vice-Chairman of the Board at the annual meeting of the Board of Directors to be held in 2004. 
  
 J. Change of Control Provisions. Notwithstanding the foregoing, all options granted under this Policy shall vest immediately if: (i) there is a Change of
Control (as hereinafter defined); and (ii) the optionee will cease to serve as a director of the Company as a result of such Change of Control. 
  
 For purposes of this Policy, a “Change of Control” shall mean: (i) a dissolution or liquidation of the Company; (ii) a sale of all or substantially all the
assets of the Company; (iii) a merger or consolidation in which the Company is not the surviving corporation and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power
entitled to vote in the election of directors has changed; (iv) a reverse merger in which the Company is the surviving corporation but the shares of the common stock of the Company outstanding immediately before the merger are converted by virtue of
the merger into other property, whether in the form of securities, cash or otherwise, and in which beneficial ownership of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the
election of directors has changed; or (v) an acquisition by any person, entity or group within the meaning of Section 13(d) or 14(d) of the Exchange Act, or any comparable successor provisions (excluding any employee benefit plan, or related trust,
sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) resulting in a change of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable
successor rule) of securities of the Company representing at least fifty percent (50%) of the combined voting power entitled to vote in the election of directors.Non-Employee Director's Stock Option Plan, as amended

 Exhibit 10.3 
  
 CV THERAPEUTICS, INC. 
  
 Non-Employee Directors’ Stock Option Plan 
  
 Amended and Restated by the Board of Directors on September 23, 1996 
 Approved by the Stockholders on October 29, 1996 
 Amended by the Board of Directors on February 23,
2000 
 Approved by the Stockholders on May 16, 2000 
 Amended and Restated by the Board of Directors on August 21, 2000 
 Amended and Restated by the
Board of Directors on February 25, 2002 
 Amended and Restated by the Board of Directors on April 15, 2002 
 Approved by the Stockholders on June 7, 2002 
 Amended and Restated by the Board of Directors on July 19, 2002 
 Amended and Restated by the Board of Directors on October
30, 2002 
 Amended and Restated by the Board of Directors on April 1, 2004 
  

	1.	 	Purpose. 

  
 (a) The purpose of the Non-Employee Directors’ Stock Option Plan (the “Plan”) is to provide a means by which each director of CV
Therapeutics, Inc. (the “Company”) who is not otherwise an employee of the Company or of any Affiliate of the Company (each such person being hereafter referred to as a “Non-Employee Director”) will be given an opportunity to
purchase stock of the Company. 
  
 (b) The word
“Affiliate” as used in the Plan means any parent corporation or subsidiary corporation of the Company as those terms are defined in Sections 424(e) and (f), respectively, of the Internal Revenue Code of 1986, as amended from time to time
(the “Code”). 
  
 (c) The Company, by means of
the Plan, seeks to retain the services of persons now serving as Non-Employee Directors of the Company, to secure and retain the services of persons capable of serving in such capacity, and to provide incentives for such persons to exert maximum
efforts for the success of the Company. 
  

	2.	 	Administration. 

  
 (a) The Plan shall be administered by the Board of Directors of the Company (the “Board”) unless and until the Board delegates
administration to a committee, as provided in subparagraph 2(b). 
  
 (b) The Board may delegate administration of the Plan to a committee composed of not fewer than two (2) members of the Board (the “Committee”). If administration is delegated to a Committee, the Committee shall have, in
connection with the administration of the Plan, the powers theretofore possessed by the Board, subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may
abolish the Committee at any time and revest in the Board the administration of the Plan. 
  

 1 

	3.	 	Shares Subject To The Plan. 

  
 (a) Subject to the provisions of paragraph 10 relating to adjustments upon changes in stock, the stock that may be sold pursuant to options granted
under the Plan shall not exceed in the aggregate five hundred fifty thousand (550,000) shares of the Company’s common stock. If any option granted under the Plan shall for any reason expire or otherwise terminate without having been exercised
in full, the stock not purchased under such option shall again become available for the Plan. 
  
 (b) The stock subject to the Plan may be unissued shares or reacquired shares, bought on the market or otherwise. 
  

	4.	 	Eligibility. 

  
 Options shall be granted only to Non-Employee Directors of the Company. 
  

	5.	 	Non-Discretionary Grants. 

  
 (a) Each person who is a Non-Employee Director on September 23, 1996 automatically shall be granted an option to purchase fifteen thousand (15,000)
shares of the Company’s common stock (after taking into account the 1:10 reverse split adopted by the Board in September 1996) on the terms and conditions set forth herein. 
  
 (b) Each person who is, after August 21, 2000, elected for the first time to be a Non-Employee Director automatically
shall, upon the date of such person’s initial election to be a Non-Employee Director by the Board or stockholders of the Company, be granted an option to purchase twenty-five thousand (25,000) shares of the Company’s common stock on the
terms and conditions set forth herein. 
  
 (c) At each
annual meeting of the stockholders following the effectiveness of the initial public offering of the Company’s common stock until and including the 1998 Annual Meeting, each person then serving as a Non-Employee Director automatically shall be
granted an option to purchase five thousand (5,000) shares of the Company’s common stock (after taking into account the 1:10 reverse split adopted by the Board in September 1996) on the terms and conditions set forth herein; at each annual
meeting of the stockholders beginning with the 1999 Annual Meeting, each person then serving as a Non-Employee Director automatically shall be granted an option to purchase seven thousand five hundred (7,500) shares of the Company’s common
stock on the terms and conditions set forth herein. 
  

	6.	 	Option Provisions. 

  
 Each option shall be subject to the following terms and conditions: 
  
 (a) The term of each option commences on the date it is granted and, unless sooner terminated as set forth herein,
expires on the date (“Expiration Date”) ten (10) years from the date of grant. If the optionee’s service as a Non-Employee Director of the Company terminates 

  

 2 

 
for any reason or for no reason, the option shall terminate on the earlier of the Expiration Date or the date six (6) months following the date of
termination of such service as a Non-Employee Director of the Company; provided, however, that if such termination of service is due to the optionee’s death, the option shall terminate on the earlier of the Expiration Date or eighteen
(18) months following the date of the optionee’s death. In any and all circumstances, an option may be exercised following termination of the optionee’s service as a Non-Employee Director of the Company only as to that number of shares as
to which it was exercisable on the date of termination of such service as a Non-Employee Director of the Company and, where the optionee provides continuous service as an employee of or consultant to the Company or any Affiliate of the Company
following termination of service as a Non-Employee Director, as to that number of shares as to which it becomes exercisable in light of such continuous service under subparagraph 6(e); provided, however, that in any and all cases all options shall
terminate on the earlier of the Expiration Date or the date six (6) months following the date of termination of service as a Non-Employee Director of the Company. 
  
 (b) Subject to applicable law, the exercise price of each option shall be the fair market value of the stock subject
to such option on the date such option is granted. 
  
 (c)
The optionee may elect to make payment of the exercise price under one of the following alternatives: 
  
 (i) Payment of the exercise price per share in cash at the time of exercise; or 
  
 (ii) Provided that at the time of the exercise the
Company’s common stock is publicly traded and quoted regularly in the Wall Street Journal, payment by delivery of shares of common stock of the Company already owned by the optionee, held for the period required to avoid a charge to the
Company’s reported earnings, and owned free and clear of any liens, claims, encumbrances or security interest, which common stock shall be valued at its fair market value on the date preceding the date of exercise; or 
  
 (iii) Payment by a combination of the methods of
payment specified in subparagraph 6(c)(i) and 6(c)(ii) above. 
  
 Notwithstanding the foregoing, this option may be exercised pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board which results in the receipt of cash (or check) by the Company prior to the issuance
of shares of the Company’s common stock. 
  
 (d) An
option shall by its terms be personal and may not be sold, pledged, assigned, transferred, encumbered or otherwise alienated or hypothecated in any manner other than by will or the laws of descent and distribution or to a Permitted Transferee (as
defined below) or by a Permitted Transferee to a Family Member (as defined below). During the lifetime of an optionee, only he or she or a Permitted Transferee may exercise an option, or any portion thereof, granted to the optionee under the Plan.

  
 (i) An option transferred to a
Permitted Transferee shall not be assignable or transferable by the Permitted Transferee to any person or entity, other than the original optionee’s Family Members. 
  

 3 

 (ii) Any option which is transferred to a Permitted Transferee shall continue to
be subject to all the terms and conditions of the option as applicable to the original optionee. 
  
 (iii) The optionee and the Permitted Transferee shall execute any and all documents reasonably requested by the Company, including
without limitation documents to (A) confirm the status of the transferee as a Permitted Transferee, (B) satisfy any requirements for an exemption for the transfer under applicable federal and state securities laws and (C) evidence the transfer. In
the event any option is exercised by, or to be paid to, the executors, administrators, heirs or distributees of the estate of a deceased optionee, or such an optionee’s beneficiary, or the transferee of an option, in any such case pursuant to
the terms and conditions of the Plan, the Company shall be under no obligation to issue stock, or make any payment, thereunder unless and until the Company is satisfied that the person or persons exercising such option, or to receive such payment,
is the duly appointed legal representative of the deceased optionee’s estate or the proper legatee or distributee thereof or the named beneficiary of such optionee, or the Permitted Transferee of such option, as applicable. 
  
 (iv) Shares of stock acquired by a Permitted
Transferee through exercise of an option may not be transferred, nor will any assignee or transferee thereof be recognized as an owner of such shares of common stock for any purpose, unless a registration statement under the Securities Act of 1933,
as amended, and any applicable state securities act with respect to such shares shall then be in effect or unless the availability of an exemption from registration with respect to any proposed transfer or disposition of such shares shall be
established to the satisfaction of counsel for the Company. 
  
 (v) For purposes of this Plan, the following terms shall have the following meanings: 
  
 A. “Permitted Transferee” shall mean a Family Member who receives an option from an optionee as a gift not for value or a
person or entity to whom an option is transferred by an optionee in a Permitted Transfer for Value. 
  
 B. “Permitted Transfer for Value” shall mean any transfer of an option (i) under a domestic relations order in a
settlement of marital property rights, or (ii) to an entity in which more than fifty percent (50%) of the voting interests are owned by Family Members (or the optionee) in exchange for an interest in that entity. 
  
 C. “Family Member” shall mean an
optionee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother in law, father in law, son in law, daughter in law, brother in law or sister in law, including adoptive
relationships, any person sharing the optionee’s household (other than a tenant or employee), a trust in which these persons have more than fifty percent of the beneficial interest, a foundation in which these persons (or the optionee) control
the management of assets, and any other entity in which these persons (or the optionee) own more than fifty percent (50%) of the voting interest. 
  
 (e) Each option shall become exercisable as follows: the initial grants described in Sections 5(a) and 5(b) shall become exercisable
(“vest”) at the rate of two and seventy-seven one hundredths percent (2.77%) per month over the thirty-six (36) months after the date of grant; and 

  

 4 

 
the annual grants described in Section 5(c) shall vest at the rate of eight and thirty-three one hundredths (8.33%) per month over the twelve-month
(12-month) period following the date of grant; provided that the optionee has, during the entire period prior to such vesting date, continuously served as a Non-Employee Director or as an employee of or consultant to the Company or any Affiliate of
the Company, whereupon such option shall become fully exercisable in accordance with its terms with respect to that portion of the shares represented by that installment. 
  
 (f) The Company may require any optionee, or any person to whom an option is transferred under subparagraph 6(d), as
a condition of exercising any such option: (i) to give written assurances satisfactory to the Company as to the optionee’s knowledge and experience in financial and business matters; and (ii) to give written assurances satisfactory to the
Company stating that such person is acquiring the stock subject to the option for such person’s own account and not with any present intention of selling or otherwise distributing the stock. These requirements, and any assurances given pursuant
to such requirements, shall be inoperative if (i) the issuance of the shares upon the exercise of the option has been registered under a then-currently-effective registration statement under the Securities Act of 1933, as amended (the
“Securities Act”), or (ii), as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then-applicable securities laws. 
  
 (g) Notwithstanding anything to the contrary contained herein, an
option may not be exercised unless the shares issuable upon exercise of such option are then registered under the Securities Act or, if such shares are not then so registered, the Company has determined that such exercise and issuance would be
exempt from the registration requirements of the Securities Act. 
  
 (h) The Company (or a representative of the underwriters) may, in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, require that any optionee not sell or
otherwise transfer or dispose of any shares of common stock or other securities of the Company during such period (not to exceed one hundred eighty (180) days) following the effective date of the registration statement of the Company filed under the
Securities Act as may be requested by the Company or the representative of the underwriters. 
  

	7.	 	Covenants Of The Company. 

  
 (a) During the terms of the options granted under the Plan, the Company shall keep available at all times the number of shares of stock required to
satisfy such options. 
  
 (b) The Company shall seek to
obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to issue and sell shares of stock upon exercise of the options granted under the Plan; provided, however, that this
undertaking shall not require the Company to register under the Securities Act either the Plan, any option granted under the Plan, or any stock issued or issuable pursuant to any such option. If, after reasonable efforts, the Company is unable to
obtain from any such regulatory commission or agency the authority which counsel for the Company deems necessary for the 

  

 5 

 
lawful issuance and sale of stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell stock upon exercise of such
options. 
  

	8.	 	Use Of Proceeds From Stock. 

  
 Proceeds from the sale of stock pursuant to options granted under the Plan shall constitute general funds of the Company. 
  

	9.	 	Miscellaneous. 

  
 (a) Neither an optionee nor any person to whom an option is transferred under subparagraph 6(d) shall be deemed to be the holder of, or to have any
of the rights of a holder with respect to, any shares subject to such option unless and until such person has satisfied all requirements for exercise of the option pursuant to its terms. 
  
 (b) Nothing in the Plan or in any instrument executed pursuant thereto shall confer upon any Non-Employee Director
any right to continue in the service of the Company or any Affiliate or shall affect any right of the Company, its Board or stockholders or any Affiliate to terminate the service of any Non-Employee Director with or without cause. 
  
 (c) No Non-Employee Director, individually or as a member of a group,
and no beneficiary or other person claiming under or through him, shall have any right, title or interest in or to any option reserved for the purposes of the Plan except as to such shares of common stock, if any, as shall have been reserved for him
pursuant to an option granted to him. 
  
 (d) In connection
with each option made pursuant to the Plan, it shall be a condition precedent to the Company’s obligation to issue or transfer shares to a Non-Employee Director, or to evidence the removal of any restrictions on transfer, that such Non-Employee
Director make arrangements satisfactory to the Company to insure that the amount of any federal or other withholding tax required to be withheld with respect to such sale or transfer, or such removal or lapse, is made available to the Company for
timely payment of such tax. 
  
 (e) As used in this Plan,
fair market value means, as of any date, the value of the common stock of the Company determined as follows: 
  
 (i) If the common stock of the Company is listed on any established stock exchange, or traded on the Nasdaq National Market or the
Nasdaq SmallCap Market, the fair market value of a share of common stock of the Company shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or market
with the greatest volume of trading in common stock of the Company) on the last market trading day prior to the day of determination, as reported in the Wall Street Journal or such other source as the Board deems reliable; 
  
 (ii) In the absence of such markets for the common
stock of the Company, the fair market value shall be determined in good faith by the Board. 
  

 6 

	10.	 	Adjustments Upon Changes In Stock. 

  
 (a) If any change is made in the stock subject to the Plan, or subject to any option granted under the Plan (through merger, consolidation,
reorganization, recapitalization, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or otherwise), the Plan and outstanding options will
be appropriately adjusted in the class(es) and maximum number of shares subject to the Plan and the class(es) and number of shares and price per share of stock subject to outstanding options. 
  
 (b) In the event of: (1) a merger or consolidation in which the
Company is not the surviving corporation; (2) a reverse merger in which the Company is the surviving corporation but the shares of the Company’s common stock outstanding immediately preceding the merger are converted by virtue of the merger
into other property, whether in the form of securities, cash or otherwise; or (3) any other capital reorganization in which more than fifty percent (50%) of the shares of the Company entitled to vote are exchanged (each, a “Change of
Control”), each outstanding option shall automatically, without any further action by the Company, become vested and exercisable with respect all of the shares of Common Stock subject thereto no later than five (5) business days before the
closing of the Change of Control. In addition, any surviving corporation, other than the Company, may assume any options outstanding under the Plan or substitute similar options for those outstanding under the Plan or, if the Company is the
surviving corporation, outstanding options may continue in full force and effect. In the event of a Change of Control in connection with which options are not assumed or substituted for by a surviving corporation or if the Company does not continue
options in full force and effect, such options shall terminate if not exercised at or prior to the closing of the Change of Control. 
  

	11.	 	Amendment Of The Plan And Options. 

  
 (a) The Board at any time, and from time to time, may amend the Plan. Except as provided in paragraph 10 relating to adjustments upon changes in
stock, no amendment shall be effective unless approved by the stockholders of the Company within twelve (12) months before or after the adoption of the amendment, where the amendment will increase the number of shares which may be issued under the
Plan. 
  
 (b) The Board at any time, and from time to time,
may amend the terms of any one or more options granted under the Plan; provided, however, that the rights and obligations under any option granted before any amendment of the Plan shall not be altered or impaired by such amendment unless (i) the
Company requests the consent of the person to whom the option was granted and (ii) such person consents in writing. Notwithstanding the foregoing, the Board shall not, without the approval of the stockholders of the Company, authorize the amendment
of any outstanding option to reduce its exercise price. Furthermore, no option shall be canceled and replaced with grants having a lower exercise price without the further approval of stockholders of the Company. 
  

	12.	 	Termination Or Suspension Of The Plan. 

  
 (a) The Board may suspend or terminate the Plan at any time. Unless sooner terminated, the Plan shall terminate on September 23, 2006. No options
may be granted under the Plan while the Plan is suspended or after it is terminated. 
  

 7 

 (b) Rights and obligations under any option granted while the Plan is in effect shall not be
altered or impaired by suspension or termination of the Plan, except with the consent of the person to whom the option was granted. 
  
 (c) The Plan shall terminate upon the occurrence of any of the events described in Section 10(b) above. 
  

	13.	 	Effective Date Of Plan; Conditions Of Exercise. 

  
 (a) This amendment and restatement of the Plan shall become effective upon adoption by the Board of Directors, subject to the condition subsequent
that this amendment and restatement of the Plan is approved by the stockholders of the Company. Following the effective date of this amendment and restatement, options shall not be granted under the terms of the Plan in effect prior to such
effective date. 
  
 (b) No option granted under the Plan
shall be exercised or exercisable unless and until the condition of subparagraph 13(a) above has been met. 
  

 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]